



ESMO Preceptorship on Breast Cancer

PROGRAMME

ESMO PRECEPTORSHIP

**SINGAPORE
29-30 NOVEMBER 2023**

Co-Chairs

Rebecca Dent, Singapore
Sherko Kümmel, Germany

ESMO PRECEPTORSHIP PROGRAMME BREAST CANCER

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

Singapore
29-30 November 2023

CHAIRS

Rebecca A. Dent, Singapore
Sherko Kümmel, Germany

SPEAKERS

Seock-Ah Im, Republic of Korea
Belinda E. Kiely, Australia
David Krug, Germany
Matteo Lambertini, Italy

Soo Chin Lee, Singapore
Lester C. H. Leong, Singapore
Frédérique Penault-Llorca, France
Yoon Sim Yap, Singapore

LEARNING OBJECTIVES

- To learn about screening, diagnosis and staging of breast cancer
- To learn about genetic testing and management of BRCA carriers
- To learn about the biology of breast cancer and its implications in the management of this disease
- To learn about the standard of care management of early, locally advanced, and metastatic breast cancer in surgery, radiation therapy and systemic therapy
- To understand the crucial role of multidisciplinary care in the management of breast cancer

ACCREDITATION

The programme of this event has been accredited with **12 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 29 November 2023

09:00-09:10 10'	Opening and welcome	
10'	Welcome and introduction	Rebecca A. Dent, SG Sherko Kümmel, DE
09:10-09:55 45'	MODULE 1 Imaging	Chair: Matteo Lambertini, IT
30'	Imaging (diagnosis, staging, high-risk breast cancer, Artificial Intelligence)	Lester C. H. Leong, SG
15'	Q&A	All
09:55-10:50 55'	MODULE 2 Biology	Chair: Rebecca A. Dent, SG
25'	New breast cancer classification and new technologies: What's relevant in everyday practice? (including Next Generation Sequencing)	Frédérique Penault-Llorca, FR
20'	Use of Genomic Assays in early breast cancer (ie. Oncotype, mammaprint etc..)	Sherko Kümmel, DE
10'	Q&A	All
10:50-11:20	Coffee break	
11:20-12:55 95'	MODULE 3 Early ER+ Breast Cancer – part I	Chair: Sherko Kümmel, DE
20'	Pregnancy: Planning for, during and after treatment	Matteo Lambertini, IT
20'	Systemic therapy for adjuvant ER+ and when is ovarian suppression warranted?	Soo Chin Lee, SG
20'	Best systemic therapy high risk ER+ HER2 negative breast cancer? (choice of chemo, role of CDKi)	Sherko Kümmel, DE
15'	Q&A	All
20'	Participants clinical case discussion (2x10')	Faculty
12:55-13:55	Lunch	
13:55-15:00 65'	MODULE 4 Local-regional treatment	Chair: David Krug, DE
25'	Surgery: What strategy is safe for breast and axilla?	Sherko Kümmel, DE
25'	Radiotherapy: How short is enough?	David Krug, DE
15'	Q&A	All
15:00-15:30	Coffee break	
15:30-16:55 85'	MODULE 5 Triple Negative Breast Cancer (TNBC)	Chairs: Rebecca A. Dent, SG Sherko Kümmel, DE
20'	What is the optimal therapy in stage I, II, III in pCR and non-pCR?	Sherko Kümmel, DE
20'	Systemic therapy for metastatic TNBC	Rebecca A. Dent, SG
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty

16:55-17:35 40'	MODULE 6 Communicating bad news to cancer patients	Chair: Belinda E. Kiely, AU
30'	Communicating bad news to cancer patients	Belinda E. Kiely, AU
10'	Q&A	All
19:00	Networking dinner	

Thursday, 30 November 2023

08:30-09:05 35'	MODULE 7 Early ER+ Breast Cancer – part II	Chair: Matteo Lambertini, IT
25'	Special issues in treatment of elderly patients	Belinda E. Kiely, AU
10'	Q&A	All
09:05-11:05 120'	MODULE 8 Issues in Advanced Breast Cancer	Chair: Rebecca A. Dent, SG
25'	Optimal choice in the first line setting ER+ Advanced Breast Cancer	Yoon Sim Yap, SG
25'	Treatment beyond first line, ER+ Advanced Breast Cancer (PIK3CA, ESR1 mutations, ADCs, AKT, etc...)	Seock-Ah Im, KR
25'	Where does HER2 low fit?	Rebecca A. Dent, SG
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
11:05-11:35	Coffee break	
11:35-12:30 55'	MODULE 9 BRCA	Chair: Rebecca A. Dent, SG
20'	Genetic counselling and testing	Soo Chin Lee, SG
20'	Management of BRCA carriers	Soo Chin Lee, SG
15'	Q&A	All
12:30-14:05 95'	MODULE 10 HER2+ Breast Cancer	Chair: Seock-Ah Im, KR
25'	Escalation and de-escalation in (neo)-adjuvant systemic therapy: What is proven?	Seock-Ah Im, KR
25'	Systemic therapy for HER2+ advanced breast cancer: Now and in future	Matteo Lambertini, IT
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
14:05-14:10 5'	Closing remarks	Rebecca A. Dent, SG Sherko Kümmel, DE
14:10-15:10	Lunch	

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion